NAVB | Navidea Biopharmaceuticals, Inc.

Index- P/E- EPS (ttm)-0.50 Insider Own26.30% Shs Outstand32.65M Perf Week-23.33%
Market Cap3.46M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float22.27M Perf Month-60.00%
Income-15.70M PEG- EPS next Q- Inst Own4.70% Short Float / Ratio0.20% / 0.02 Perf Quarter-69.33%
Sales0.07M P/S52.73 EPS this Y-39.30% Inst Trans0.28% Short Interest0.04M Perf Half Y-60.85%
Book/sh-0.30 P/B- EPS next Y- ROA-405.20% Target Price- Perf Year-88.05%
Cash/sh0.00 P/C- EPS next 5Y- ROE226.20% 52W Range0.08 - 1.05 Perf YTD-56.19%
Dividend- P/FCF- EPS past 5Y20.00% ROI- 52W High-91.24% Beta1.55
Dividend %- Quick Ratio0.10 Sales past 5Y- Gross Margin- 52W Low11.52% ATR0.02
Employees11 Current Ratio0.10 Sales Q/Q- Oper. Margin- RSI (14)27.28 Volatility21.74% 15.60%
OptionableYes Debt/Eq- EPS Q/Q54.30% Profit Margin- Rel Volume1.65 Prev Close0.09
ShortableYes LT Debt/Eq- EarningsMar 21 AMC Payout- Avg Volume1.87M Price0.09
Recom2.00 SMA20-31.75% SMA50-57.62% SMA200-65.55% Volume3,129,664 Change2.00%
Date Action Analyst Rating Change Price Target Change
Nov-13-13Reiterated Aegis Capital Hold $3 → $2
Nov-07-13Reiterated Ladenburg Thalmann Buy $7.50 → $3
Jan-24-13Initiated Burrill Institutional Research Mkt Outperform $5
Jan-22-13Initiated Aegis Capital Hold $3
Sep-11-12Reiterated WBB Securities Strong Buy $9 → $7
Sep-11-12Reiterated Rodman & Renshaw Mkt Outperform $7 → $6
Sep-11-12Reiterated Ladenburg Thalmann Buy $6.25 → $7.50
May-22-23 06:30PM
May-11-23 05:35PM
May-08-23 04:12PM
Apr-27-23 05:14PM
Apr-13-23 04:50PM
05:02PM Loading…
Mar-30-23 05:02PM
Mar-24-23 07:36AM
Mar-22-23 08:28AM
Mar-21-23 04:01PM
Mar-15-23 07:30AM
Jan-03-23 08:30AM
Dec-28-22 09:59AM
Nov-30-22 08:04PM
Nov-28-22 08:30AM
Nov-14-22 05:23PM
08:00AM Loading…
Nov-07-22 04:05PM
Nov-04-22 07:30AM
Oct-05-22 04:30PM
Sep-30-22 08:30AM
Sep-15-22 08:30AM
Sep-08-22 04:00PM
Sep-01-22 08:30AM
Aug-30-22 09:30AM
Aug-25-22 09:16AM
Aug-18-22 08:26AM
Aug-15-22 08:30AM
Aug-04-22 07:30AM
Aug-01-22 04:30PM
07:30AM Loading…
Jul-25-22 07:30AM
Jul-20-22 08:57AM
Jul-05-22 08:00AM
May-24-22 08:30AM
May-23-22 07:30AM
May-12-22 07:30AM
May-05-22 07:30AM
Apr-20-22 06:58AM
Apr-18-22 04:01PM
Apr-12-22 04:05PM
Apr-07-22 07:30AM
Mar-23-22 03:44PM
Mar-16-22 07:30AM
Feb-07-22 07:30AM
Feb-03-22 04:01PM
Dec-16-21 04:01PM
Dec-15-21 04:02PM
Dec-13-21 07:30AM
Dec-09-21 04:01PM
Nov-04-21 03:01PM
Nov-03-21 04:01PM
Oct-26-21 05:22PM
Oct-14-21 07:30AM
Sep-27-21 07:30AM
Sep-20-21 09:07AM
Sep-17-21 07:30AM
Aug-11-21 05:15PM
Aug-04-21 07:30AM
Jul-19-21 07:30AM
Jul-15-21 07:30AM
Jun-24-21 07:00AM
Jun-14-21 07:32PM
May-19-21 07:30AM
May-11-21 04:01PM
May-05-21 08:00AM
May-04-21 07:30AM
Apr-15-21 07:30AM
Mar-24-21 04:21PM
Mar-17-21 07:30AM
Mar-02-21 04:01PM
Feb-09-21 08:09AM
Feb-08-21 04:05PM
Jan-07-21 07:30AM
Dec-28-20 07:30AM
Dec-08-20 09:51AM
Nov-26-20 06:34PM
Nov-12-20 04:02PM
Nov-05-20 04:01PM
Oct-29-20 12:35PM
Oct-22-20 07:30AM
Oct-09-20 07:30AM
Sep-28-20 07:30AM
Sep-08-20 04:05PM
Sep-02-20 04:05PM
Aug-31-20 05:00PM
Aug-24-20 04:05PM
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.